One Day One Graph at EASD

Featured Graph
During the EASD conference, I selected one graph per day that I found interesting to comment and promote among the presentation I listen to (these graphs were published during the conference on LinkedIn ( ) and Twitter (

Day 1

A graph presented by Dr. Katarina Eeg-Olofsson of the improvement of A1c in T1D patients in Sweden (data from the National Diabetes Register in Sweden) showing a constant reduction of the number of patients with high A1c and a number of patients with an A1c below 6.5% that more than doubled in 20 years. A very different result than the well known and used graph from the T1D Exchange registry in the US. Is it a consequence of the differences in healthcare systems between the 2 countries? It gives hope and motivation to see such results!

Day 2

The results of a Phase 2 trial testing golimumab, an already approved monoclonal antibody for other auto-immune diseases in newly diagnosed T1D. One of the projects developed to help patients preserving part of their pancreas that we know can be key to make diabetes management easier. I am looking forward to seeing how this exciting field of innovation will help patients.

The graph shows a slower decrease of C-peptide that is a marker of beta-cell and so pancreas function.

Day 3

A graph presented during the great IHSG symposium on the clinical impact of hypoglycemia by Dr. Khunti from the HAT study. It compares self-reported hypoglycemia before (retrospective) and during (prospective) an observational trial in 24 countries. It shows how patients under-report hypoglycemia, even if they are so important to adjust treatments. It also makes it difficult to reveal the real burden of hypoglycemia still too high!

This symposium also included a very interesting presentation from Dr. Amiel on what’s achievable and what’s enough as a reduction of hypoglycemia!

Day 4

You all know this type of graph, the median and quartile CGM values of 2 different treatments. Here is a graph presented by the Pr. Benhamou during the Diabeloop symposium comparing the use of their hybrid closed-loop system with a predictive low glucose management system (PLGM). I am choosing this graph because it’s the first study I know that was done in T1D with highly uncontrolled and variable blood glucose levels, patients that are eligible for islet transplantation because no other solutions can help them. Here we see an increase of time in range from 43.5% to 73.3%. One example that gives hope for these patients that struggle so much with their diabetes. I look forward to seeing similar studies with other systems

Day 5

A graph presented by Katarina Steen Carlsson during a presentation on the cost of diabetes complications in T2D in Sweden showing the network of comorbidity interactions in this population. It shows how important it is to have interdisciplinary approaches to treat diabetes and prevent comorbidities as there are so many interactions between different medical fields and as these comorbidities are so frequent

The key R&D results presented during this conference will be included in my next R&D diabetes news.

Share Post
Share on facebook
Share on linkedin
Share on twitter
Share on pinterest
Share on email